β2-微球蛋白与C反应蛋白水平在心力衰竭中的研究进展
Research Progress on β2-Microglobulin and C-Reactive Protein Levels in Heart Failure
DOI: 10.12677/acm.2026.1662421, PDF,    科研立项经费支持
作者: 张盛祺, 陆爱民*：青海省心脑血管病专科医院冠心病二科，青海 西宁
关键词: β2-微球蛋白；C反应蛋白；心力衰竭；生物标志物；炎症反应；预后评估；β2-Microglobulin； C-Reactive Protein； Heart Failure； Biomarkers； Inflammatory Response； Prognosis Assessment
摘要: 心力衰竭作为各类心血管疾病的终末期表现，其发生与进展往往伴随着持续的炎症反应及代谢紊乱。在心力衰竭的病理生理过程中，β2-微球蛋白(β2-MG)与C反应蛋白(CRP)是两项重要的生物标志物，前者主要反映肾功能状态，后者则常用于评估全身炎症水平。近年来的临床研究表明，这两种标志物的水平变化与心衰患者的疾病严重程度密切相关，同时在诊断鉴别、风险分层、预后评价以及治疗反应追踪等方面均显示出重要的临床应用价值。本文将对β2-MG与CRP在心力衰竭中的作用机制及相关临床研究进行系统梳理。
Abstract: As the terminal manifestation of various cardiovascular diseases, heart failure is often accompanied by persistent inflammatory responses and metabolic disorders in its occurrence and progression. In the pathophysiological process of heart failure, beta-2-microglobulin (β2-MG) and C-reactive protein (CRP) are two important biomarkers. The former mainly reflects renal function status, while the latter is commonly used to evaluate systemic inflammation levels. Recent clinical studies have shown that changes in the levels of these two markers are closely related to the severity of heart failure in patients. Moreover, they demonstrate significant clinical application value in diagnosis and differential diagnosis, risk stratification, prognosis evaluation, and tracking treatment response. This article will systematically review the mechanisms of action of β2-MG and CRP in heart failure and related clinical research.
文章引用：张盛祺, 陆爱民. β2-微球蛋白与C反应蛋白水平在心力衰竭中的研究进展[J]. 临床医学进展, 2026, 16(6): 2014-2022. https://doi.org/10.12677/acm.2026.1662421

参考文献

[1] Wróbel-Nowicka, K., Wojciechowska, C., Jacheć, W., Zalewska, M. and Romuk, E. (2024) The Role of Oxidative Stress and Inflammatory Parameters in Heart Failure. Medicina, 60, Article 760. [Google Scholar] [CrossRef] [PubMed]
[2] Amara, M., Stoler, O. and Birati, E.Y. (2025) The Role of Inflammation in the Pathophysiology of Heart Failure. Cells, 14, Article 1117. [Google Scholar] [CrossRef] [PubMed]
[3] Ohuchi, H., Asano, R., Mori, A., Ishibashi, T., Motooka, D., Nakai, M., et al. (2024) Gut Dysbiosis in Patients with Fontan Circulation. Journal of the American Heart Association, 13, e034538. [Google Scholar] [CrossRef] [PubMed]
[4] Namiuchi, S., Nochioka, K., Ushigome, R., Sunamura, S., Tanita, A., Ogata, T., et al. (2025) Systemic Inflammation-Based Glasgow Prognostic Score as a Prognostic Indicator in Chronic Heart Failure. IJC Heart & Vasculature, 58, Article 101660. [Google Scholar] [CrossRef] [PubMed]
[5] Saha, S., Singh, P., Dutta, A., et al. (2025) A Systems Proteo-Lipidomic Approach Identifies Novel Circulatory Biomarkers for Idiopathic Dilated Cardiomyopathy. American Journal of Physiology-Heart and Circulatory Physiology, 33, H212-H229. [Google Scholar] [CrossRef] 
[6] Otaki, Y., Watanabe, T., Shimizu, M., Tachibana, S., Sato, J., Kobayashi, Y., et al. (2023) Renal Tubular Damage and Clinical Outcome in Heart Failure with Preserved Ejection Fraction and Chronic Kidney Disease. ESC Heart Failure, 10, 2458-2468. [Google Scholar] [CrossRef] [PubMed]
[7] Jiang, S., Carroll, L., Mariotti, M., Hägglund, P. and Davies, M.J. (2021) Formation of Protein Cross-Links by Singlet Oxygen-Mediated Disulfide Oxidation. Redox Biology, 41, Article 101874. [Google Scholar] [CrossRef] [PubMed]
[8] Jheng, J., DesJardin, J.T., Chen, Y., Huot, J.R., Bai, Y., Cook, T., et al. (2024) Plasma Proteomics Identifies B2M as a Regulator of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction. Arteriosclerosis, Thrombosis, and Vascular Biology, 44, 1570-1583. [Google Scholar] [CrossRef] [PubMed]
[9] Maio, R., Perticone, M., Suraci, E., Sciacqua, A., Sesti, G. and Perticone, F. (2021) Endothelial Dysfunction and C-Reactive Protein Predict the Incidence of Heart Failure in Hypertensive Patients. ESC Heart Failure, 8, 399-407. [Google Scholar] [CrossRef] [PubMed]
[10] Fatima, Z., Shakeel, R., Chaudhry, S.A.A., Qadri, M., Kakar, A.I., Ahmad, B., et al. (2025) The Relation between C-Reactive Protein (CRP) and Risk of Incident Heart Failure in Patients with Cardiovascular Disease: A Narrative Review. Annals of Medicine & Surgery, 87, 4356-4361. [Google Scholar] [CrossRef] [PubMed]
[11] Burger, P.M., Koudstaal, S., Mosterd, A., Fiolet, A.T.L., Teraa, M., van der Meer, M.G., et al. (2023) C-Reactive Protein and Risk of Incident Heart Failure in Patients with Cardiovascular Disease. Journal of the American College of Cardiology, 82, 414-426. [Google Scholar] [CrossRef] [PubMed]
[12] Sarraf, M., Masoumi, A. and Schrier, R.W. (2009) Cardiorenal Syndrome in Acute Decompensated Heart Failure. Clinical Journal of the American Society of Nephrology, 4, 2013-2026. [Google Scholar] [CrossRef] [PubMed]
[13] Salman, O., Zhao, L., Cohen, J.B., Dib, M.J., Azzo, J.D., Gan, S., Richards, A.M., et al. (2024) Proteomic Correlates and Prognostic Significance of Kidney Injury in Heart Failure with Preserved Ejection Fraction. Journal of the American Heart Association, 13, e033660.
[14] Ronco, C., House, A.A. and Haapio, M. (2008) Cardiorenal Syndrome: Refining the Definition of a Complex Symbiosis Gone Wrong. Intensive Care Medicine, 34, 957-962. [Google Scholar] [CrossRef] [PubMed]
[15] Silverstein, D.M. (2009) Inflammation in Chronic Kidney Disease: Role in the Progression of Renal and Cardiovascular Disease. Pediatric Nephrology, 24, 1445-1452. [Google Scholar] [CrossRef] [PubMed]
[16] Zhou, X.J., Zhang, X., Zhang, J., Zhou, L., Zhou, T.T. and Zhang, J.W. (2020) Diagnostic Value of Growth Differentiation Factor-15 and β2-Microglobulin in Children with Congenital Heart Disease Combined with Chronic Heart Failure and Its Relationship with Cardiac Function. European Review for Medical and Pharmacological Sciences, 24, 8096-8103.
[17] Wang, Q., An, Y., Wang, H., Zhang, N. and Deng, S. (2021) The Clinical Significance of Changes in cTnT, CRP and NT-proBNP Levels in Patients with Heart Failure. American Journal of Translational Research, 13, 2947-2954.
[18] He, Q., Cao, Y., Fan, X., Li, B., He, Q. and Zhang, H. (2025) Long-Term Prognostic Value of CRP-Albumin-Lymphocyte Index in Elderly Patients with Heart Failure with Preserved Ejection Fraction. Experimental Gerontology, 204, Article 112744. [Google Scholar] [CrossRef] [PubMed]
[19] Cui, X., Zou, Y., Gao, W., et al. (2023) Volume Management of Intermittent Hemofiltration Guided by Critical Care Ultrasound in the Treatment of Acute Kidney Injury. Chinese Critical Care Medicine, 35, 310-315.
[20] Christoph, W. and Thomas, M. (2002) C-Reactive Protein a Marker for All-Cause and Cardiovascular Mortality in Haemodialysis Patients. Nephrology Dialysis Transplantation, 17, 29-32. [Google Scholar] [CrossRef] [PubMed]
[21] García, M., Llàcer, P., Croset, F., Campos, J., Pérez, C., Pérez, A., et al. (2025) Prognostic Impact of C-Reactive Protein in Elderly Patients with Acute Heart Failure and Preserved Ejection Fraction: The Modulating Role of Carbohydrate Antigen 125. Frontiers in Cardiovascular Medicine, 12, Article ID: 1611644. [Google Scholar] [CrossRef] 
[22] Kuster, N., Huet, F., Dupuy, A., Akodad, M., Battistella, P., Agullo, A., et al. (2020) Multimarker Approach Including CRP, Sst2 and GDF-15 for Prognostic Stratification in Stable Heart Failure. ESC Heart Failure, 7, 2230-2239. [Google Scholar] [CrossRef] [PubMed]
[23] Liuzhuang, X., Yang, S., Yang, Y., Gu, W., Shi, T., Xu, C., et al. (2025) Relationship between the HDL-C/CRP Ratio and All-Cause Mortality in Patients with Chronic Heart Failure: A Retrospective Analysis from Yunnan Province, China. BMJ Open, 15, e084099. [Google Scholar] [CrossRef] [PubMed]
[24] Sheriff, A., Kunze, R., Brunner, P. and Vogt, B. (2023) Being Eaten Alive: How Energy-Deprived Cells Are Disposed Of, Mediated by C-Reactive Protein—Including a Treatment Option. Biomedicines, 11, 2279. [Google Scholar] [CrossRef] [PubMed]
[25] Han, X., Guo, X., Chang, J., Zhang, J., Chen, L., Wang, H., et al. (2022) Integrinβ3 Mediates the Protective Effects of Soluble Receptor for Advanced Glycation End-Products during Myocardial Ischemia/reperfusion through AKT/STAT3 Signaling Pathway. Apoptosis, 27, 354-367. [Google Scholar] [CrossRef] [PubMed]
[26] Ma, R., Gao, L., Liu, Y., Du, P., Chen, X. and Li, G. (2021) LncRNA TTTY15 Knockdown Alleviates H2O2-Stimulated Myocardial Cell Injury by Regulating the miR-98-5p/CRP Pathway. Molecular and Cellular Biochemistry, 476, 81-92. [Google Scholar] [CrossRef] [PubMed]
[27] Zhang, K., Tian, X., Li, W. and Hao, L. (2023) Ferroptosis in Cardiac Hypertrophy and Heart Failure. Biomedicine & Pharmacotherapy, 168, Article 115765. [Google Scholar] [CrossRef] [PubMed]
[28] Kayser, S., Brunner, P., Althaus, K., Dorst, J. and Sheriff, A. (2020) Selective Apheresis of C-Reactive Protein for Treatment of Indications with Elevated CRP Concentrations. Journal of Clinical Medicine, 9, Article 2947. [Google Scholar] [CrossRef] [PubMed]
[29] Stec-Martyna, E., Wojtczak, K., Nowak, D. and Stawski, R. (2025) Battle of the Biomarkers of Systemic Inflammation. Biology, 14, Article 438. [Google Scholar] [CrossRef] [PubMed]
[30] Tiller, C., Reindl, M., Holzknecht, M., Lechner, I., Oberhollenzer, F., von der Emde, S., et al. (2025) Association of Intramyocardial Hemorrhage with Inflammatory Biomarkers in Patients with ST-Segment Elevation Myocardial Infarction. JACC: Advances, 4, Article 101647. [Google Scholar] [CrossRef] [PubMed]
[31] Tiller, C., Reindl, M., Holzknecht, M., Lechner, I., Simma, F., Schwaiger, J., et al. (2021) High Sensitivity C-Reactive Protein Is Associated with Worse Infarct Healing after Revascularized St-Elevation Myocardial Infarction. International Journal of Cardiology, 328, 191-196. [Google Scholar] [CrossRef] [PubMed]
[32] Amsterdam, E.A., et al. (2014) 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 130, e344-e426.
[33] Kawai, K., Kawashima, S., Miyazaki, T., Tajiri, E., Mori, M., Kitazaki, K., et al. (2010) Serum Beta2-Microglobulin Concentration as a Novel Marker to Distinguish Levels of Risk in Acute Heart Failure Patients. Journal of Cardiology, 55, 99-107. [Google Scholar] [CrossRef] [PubMed]
[34] Zhu, A., Zhang, J., Zhou, S., Ge, D., Zhang, X., Hu, M., et al. (2025) High-Sensitivity C-Reactive Protein and 6-Month All-Cause Mortality in Chinese Heart Failure Patients. Scientific Reports, 15, Article No. 32817. [Google Scholar] [CrossRef] 
[35] Ahtesham, M., Khan, S.W., Khan, S.R., Fayyaz, A., Khan, Z., Ullah, I., et al. (2025) C-Reactive Protein (CRP) Levels as a Predictor of Adverse Cardiovascular Events in Acute Myocardial Infarction: A Prospective Study. Cureus, 17, e93943. [Google Scholar] [CrossRef] 
[36] Januzzi, J.L., van Kimmenade, R., Lainchbury, J., Bayes-Genis, A., Ordonez-Llanos, J., Santalo-Bel, M., et al. (2005) NT-proBNP Testing for Diagnosis and Short-Term Prognosis in Acute Destabilized Heart Failure: An International Pooled Analysis of 1256 Patients: The International Collaborative of NT-proBNP Study. European Heart Journal, 27, 330-337. [Google Scholar] [CrossRef] [PubMed]
[37] 中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024 [J]. 中华心血管病杂志, 2024, 52(3): 235-275.
[38] Nazir, A., Nazir, A., Afzaal, U., Aman, S., Sadiq, S.U.R., Akah, O.Z., et al. (2025) Advancements in Biomarkers for Early Detection and Risk Stratification of Cardiovascular Diseases—A Literature Review. Health Science Reports, 8, e70878. [Google Scholar] [CrossRef] [PubMed]
[39] Brunner-La Rocca, H., Eurlings, L., Richards, A.M., Januzzi, J.L., Pfisterer, M.E., Dahlström, U., et al. (2015) Which Heart Failure Patients Profit from Natriuretic Peptide Guided Therapy? A Meta-Analysis from Individual Patient Data of Randomized Trials. European Journal of Heart Failure, 17, 1252-1261. [Google Scholar] [CrossRef] [PubMed]
[40] 江涛, 王昌富, 李军. 肾功能不全对应用NT-ProBNP诊断心力衰竭的影响[J]. 国际检验医学杂志, 2014, 35(10): 1343-1344.
[41] Rivera, M., Cortés, R., Salvador, A., Bertomeu, V., de Burgos, F.G., Payá, R., et al. (2005) Obese Subjects with Heart Failure Have Lower N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Irrespective of Aetiology. European Journal of Heart Failure, 7, 1168-1170. [Google Scholar] [CrossRef] [PubMed]
[42] Alonso, N., Lupón, J., Barallat, J., de Antonio, M., Domingo, M., Zamora, E., et al. (2016) Impact of Diabetes on the Predictive Value of Heart Failure Biomarkers. Cardiovascular Diabetology, 15, Article No. 151. [Google Scholar] [CrossRef] [PubMed]

为你推荐